[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635085":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":39,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Pennsylvania","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants diagnosed with Abdominal Aortic Aneurysm (AAA)",null,"Established diagnosis of abdominal aortic aneurysm based on standard clinical criteria.",[13],"Drug: 64Cu-DOTA-ECL1i",{"label":15,"type":10,"description":16,"interventionNames":17},"Control Group","Age-matched participants without a diagnosis of AAA as a control group.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","64Cu-DOTA-ECL1i","The radiotracer 64Cu-DOTA-ECL1i will be used to assess the aortic wall in individuals with AAA and age-matched participants without a diagnosis of AAA as a control group.",[15,9],[25],{"name":26,"affiliation":27,"role":28},"Scott M Damrauer, MD","Penn Medicine Division of Vascular Surgery","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Erin Schubert","CONTACT","215-573-6569","erin.schubert@pennmedicine.upenn.edu",{"name":36,"role":32,"phone":37,"phoneExt":10,"email":38},"Mary Hansbury","215-746-8192","mary.hansbury@pennmedicine.upenn.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":10},"Penn Medicine; Perelman School of Medicine","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-75.16362,39.95238,{"lat":52,"lon":51},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100635085","molecular-imaging-of-the-underlying-mechanism-of-vessel-wall-inflammation-using-positron-emission-tomography-petct-100635085",false,"NCT07548099","Molecular Imaging of the Underlying Mechanism of Vessel Wall Inflammation Using Positron Emission Tomography (PET\u002FCT)","Inclusion Criteria:\n\n1. Participants will be at least 18 years of age\n2. Have an established diagnosis of abdominal aortic aneurysm based on standard clinical criteria or are an age matched control with absence of known AAA.\n3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n1. Females who are pregnant or breast feeding at the time of the PET\u002FCT scan will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential before the injection of radiotracer.\n2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n3. Patients with chronic renal disease whose GFR is less than 40 mL\u002Fmin\u002F1.73m² at the time of enrollment.\n4. Documented allergy to iodinated contrast\n5. Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study\n6. Less than 6 months life expectancy as deemed by the treating physician at the time of initial enrollment.",true,"ALL","18 Years",{"count":66,"type":67},30,"ESTIMATED","OBSERVATIONAL","This research study is being conducted to test how an imaging drug called 64Cu-DOTA-ECL1i can be used to image an abdominal aortic aneurysm. 64Cu-DOTA-ECL1i is a drug used with an imaging test called a PET\u002FCT (Positron Emission Tomography\u002FComputed Tomography).\n\nThe aim is to collect data using a new imaging drug called 64Cu-DOTA-ECL1i that may be able to create images of inflammation in the aorta, which is thought to be important in how aneurysms grow and develop and to understand how consistent these scans are across time and what might affect the inflammation.",[71],"Abdominal Aortic Aneurysm",[73,74],"aortic aneurysm","aortic inflammation","2026-05-21",{"date":77,"type":78},"2026-05-22","ACTUAL",{"date":80,"type":78},"2026-04-30",{"date":82,"type":67},"2029-04-30",{"name":5,"class":6},1]